del(5q) in acute lymphoblastic leukemia with biphenotypic and early progenitor phenotype

Theodossiou, Chris; Scalise, Angela; Troy, Kevin; Perdahl-Wallace, Eva; Najfeld, Vesna

doi:10.1016/0165-4608(92)90385-l

Cited by 15 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As demonstrated for monosomy 7, 20,21 monosomy 5 and del (5q) are also genetic aberrations of multipotent stem cells leading to multilineage antigen expression patterns in the resulting leukemias. [33][34][35] We have previously found that patients with del (5q) and/or del (7q) represent a subgroup of AML patients with particularly poor prognosis possibly related to the dual expression of CD34 and P-glycoprotein by their blasts. 36 Both Ph chromosome-positive AML patients with monosomy 7 and the patient with monosomy 5/del (5q) expressed CD34 on all and P-glycoprotein on у30% of leukemic cells.…”

Section: Discussionmentioning

confidence: 99%

Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience

et al. 1998

View full text Add to dashboard Cite

Evaluable karyotypes were available in 776 of 1148 adult patients who were entered on acute myeloid leukemia (AML) treatment protocols of the Eastern Cooperative Oncology Group. Among these, we found seven patients (0.9%) with t(9;22)(q34;q11), the Philadelphia (Ph) chromosome, in bone marrow metaphases. All fulfilled the FAB criteria for AML (three M0, two M1, two M2), although one patient presented with an additional, distinct lymphoid blast cell population. Chromosomal aberrations in addition to the Ph chromosome were seen in four patients (including two cases of monosomy 7). Molecular analysis by polymerase chain reaction in four patients tested revealed variable BCR/ABL transcript forms (ela2, b2a2, b3a2, b2a3+e1a2). By immunophenotyping, all seven patients were myeloid based on the overall antigen expression pattern. However, all but one demonstrated lymphoid-associated antigens on the myeloid blast cells. The six evaluable patients failed to respond to treatment with a standard anthracycline/cytosine arabinoside-containing regimen. We conclude that the incidence of the Ph chromosome in AML is very low. Although both genotypically and phenotypically heterogenous, Ph chromosome-positive AML, represents a clinically distinct entity with poor outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience

et al. 1998

View full text Add to dashboard Cite

show abstract

“…[28][29][30][31][32][33] The remaining one was an ALL. 34 In four of the six cases of MDS RA, the translocation was found in association with del(5q). [30][31][32][33] These findings, therefore, suggest that this abnormality may be preferentially associated with deletion of 5q− in cases with the clinical characteristics of 5q− syndrome.…”

Section: A Overall Cases In 'Other' Groupmentioning

confidence: 91%

“…The single case of ALL, also, showed a deletion of 5q as a secondary change as part of a complex evolving karyotype. 34 3. Abnormalities of chromosome 3:…”

Section: A Overall Cases In 'Other' Groupmentioning

confidence: 99%

Ten novel 11q23 chromosomal partner sites

Cuneo²,

et al. 1998

View full text Add to dashboard Cite

The MLL gene located at 11q23 has been described as a 'promiscuous' gene due its involvement with a large number of genetic partners. The EU Concerted Action Workshop on 11q23 provided 550 cases for study of which 82 showed abnormalities which did not involve the established translocations or deletion of 11q23. In these 'other' cases, which included inversions and duplications, 11q23 was found to be involved with 25 chromosome partners of which 10 had not been previously reported. These were 1q31, 4p11, 6q13, 8q21, 10q22, 10q25, 11q11, 11q21, 13q34 and 18q23. This study demonstrated the value of the Workshop, in confirming the diversity of chromosomal partner sites involved with 11q23 and in the identification of new partners.

show abstract

“…In contrast to its presence in AML, del(5) (q) in ALL is not an adverse prognostic indicator, and it appears to be more frequent in children. [10] Our patient is an adult and has been diagnosed as having T-ALL by flow cytometry and ALL-L2 by morphology. The patient is undergoing treatment and will be followed up to evaluate the prognostic significance of del(5)(q).…”

Section: Discussionmentioning

confidence: 99%

An uncommon case of an adult with del(5)(q) in acute lymphoblastic leukemia

et al. 2012

View full text Add to dashboard Cite

Del(5)(q) is a common chromosomal abnormality with favourable prognosis in Myelodysplastic Syndrome (MDS) and Acute myeloid leukemia (AML). However, del(5)(q) is also seen rarely in Acute lymphoblastic leukemia (ALL) and its significance remains poorly understood. We present here, a case report of diagnosis of an adult 75 year old patient of ALL with a cytogenetic abnormality of del(5)(q32). His clinical features, morphology and immunophenotyping findings were suggestive of T-ALL. Relevant literature has been reviewed and discussed.

show abstract

del(5q) in acute lymphoblastic leukemia with biphenotypic and early progenitor phenotype

Cited by 15 publications

References 37 publications

Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience

Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience

Ten novel 11q23 chromosomal partner sites

An uncommon case of an adult with del(5)(q) in acute lymphoblastic leukemia

Contact Info

Product

Resources

About